Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

razoxane

Known as: 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+-)-, Razoxane [Chemical/Ingredient] 
An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic… Expand
National Institutes of Health

Related topics

Related topics

20 relations

Narrower (10)

ADR 559AT 2153Dexrazoxane hydrochlorideFMI protocol
Expand

Broader (1)

Antimitotic Agents
DexrazoxaneIn Bloodagonistsanalogs & derivatives
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas.
BACKGROUND Chondrosarcomas and chordomas are reported to have low radio-sensitivity. Therefore, a study was undertaken to explore… Expand
Highly Cited
2003
Highly Cited
2003
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane
Measurement of tumour and normal tissue perfusion in vivo in cancer patients will aid the clinical development of antiangiogenic… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
1998
Highly Cited
1998
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis 
Highly Cited
1994
Highly Cited
1994
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and…
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 5
Review
1991
Review
1991
Radiotherapeutic enhancement by razoxane.
Razoxane blocks cell division in the G2/M phase of the cell generation cycle and appears to normalize tumour neovasculature… Expand
1986
1986
Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: Five‐year follow‐up
Razoxane is one of the few agents which has shown activity in the treatment of advanced colorectal cancer. The drug has therefore… Expand
Review
1983
Review
1983
Doxorubicin (adriamycin) cardiomyopathy.
Despite its vast utility in clinical oncology, the use of doxorubicin hydrochloride (Adriamycin) is limited by a potentially… Expand
1982
1982
Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
: In this multi-institutional study of advanced gastric cancer, 73 patients were evaluable for response or survival. Patients… Expand
1981
1981
Reduction of daunomycin toxicity by razoxane.
A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg… Expand
  • figure 1
  • table 1
  • table II
  • table III
  • figure 5
Highly Cited
1980
Highly Cited
1980
Razoxane (ICRF 159) in the treatment of psoriasis
This paper describes our experience with the use of razoxane (ICRF 159), a new anti‐mitotic drug, in the treatment of thirty‐six… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE